Observational studyClinical rheumatology2026
The association between CD14 (C-159T) single-nucleotide polymorphism and Behcet's syndrome and its clinical manifestations in Egyptian patients, an observational case-control genetic association study.
Observational study in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCluster of differentiation 14 (CD14) molecules are immune cell surface molecules that bind and display lipopolysaccharides (LPSs) of gram-negative bacteria to Toll-like receptor 4 (TLR4), facilitating LPS-induced immune cell activation. The CD14 promoter polymorphism C-159T is positively correlated with CD14, and homozygous carriers of the T allele have a significant increase in soluble and membrane-bound CD14.
objectiveTo assess the C-159T polymorphism in Behcet patients compared to controls, and to study its relationship with disease manifestations and activity.
methodsFifty-one adult Egyptian patients with Behcet's syndrome and another 51 healthy controls were recruited. Behcet's syndrome activity was assessed. A blood sample was obtained from each participant for DNA extraction. The extracted DNA was used to determine the C-159T polymorphism in the CD14 promoter gene (rs2569190) using real-time polymerase chain reaction.
resultsThe prevalence of the TT genotype was higher in Behcet patients (23.7%) in comparison to the controls (8%) (OR = 5.3, P value = 0.01). The prevalence of the T allele was higher in Behcet patients (49.1%) in comparison to the controls (31.4%) (OR = 2.1, P value = 0.01). The skin erythema was found to be significantly (P value = 0.003) higher in frequency among the TT genotype (58.3%) compared to the CT genotype (26.9%). Moreover, the skin pustules were found to be significantly (P value = 0.01) higher in frequency among the TT genotype (41.6%) compared to the CT genotype (11.5%).
conclusionCD14 (C-159T) polymorphism is associated with an increased risk of developing Behcet's syndrome and is correlated with its dermatological manifestations. Key points • Behcet's syndrome is a variable-vessel vasculitis in which aberrant innate immunity is integral to the pathogenesis of the disease. • CD14 molecules recognize pathogens with subsequent activation of innate immunity. • The CD14 promoter gene C-159T single-nucleotide polymorphism increases the susceptibility to Behcet's syndrome. • The C-159T polymorphism correlates with skin manifestations of Behcet's syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.